Malin Corporation PLC Notice of 2022 Interim Results (1253X)

TIDM0Y71

RNS Number : 1253X

Malin Corporation PLC

25 August 2022

Malin Corporation plc

Notice of 2022 Interim Results

Dublin-Ireland, 25 August 2022 : Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin" or "the Company"), a company investing in highly innovative life sciences companies, intends to announce its interim financial results and publish its interim report for the six month period ended 30 June 2022 at 07:00am Irish Standard Time / BST on Wednesday, 7 September 2022.

Darragh Lyons, Chief Executive Officer, will host a conference call at 12:00pm Irish Standard Time / BST on the day of publication. This call can be accessed as follows:

   From Ireland dial:                             01 53695 84 
   From the UK dial:                              020 3936 2999 
   From the USA dial:                            1 646 664 1960 
   From all other locations dial:          [phone] 
   Participant access code:               978118 

The Company's results press release and presentation will be available on the Company's website from 07:00am Irish Standard Time / BST on 7 September 2022 at www.malinplc.com .

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information contact:

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information please contact:

Malin

Fiona Dunlevy, Company Secretary

Tel: [phone]

[e-mail]

Davy Corporate Finance (Euronext Growth Listing Sponsor & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: [phone]

Liberum (Joint Broker)

Phil Walker / Ben Cryer

Tel: [phone]

Powerscourt (Media enquiries)

Eavan Gannon

Tel: [phone]

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORFLFFETRISFIF

(END) Dow Jones Newswires

August 25, 2022 02:00 ET (06:00 GMT)